相关实验视频

Updated: Sep 19, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

发现高度选择性的CYP1B1抑制剂

Ting Wang^1,2, Haoyu Zhang^1,2, Dihan Tan^1,2

¹Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.

Journal of medicinal chemistry

|June 16, 2025

概括

一种新型化合物B20通过抑制CYP1B1.1,有效地克服了帕克利塔塞尔耐药性. 这种候选药物在使抗癌细胞重新敏感和抑制瘤细胞迁移方面表现有前途.

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
癌症生物学癌症生物学

背景情况:

瘤抗药性,特别是对帕克利塔塞尔的抗药性,是癌症治疗的一个主要障碍.
细胞染色体P450 1B1 (CYP1B1) 已成为帕克利塔克塞尔耐药性的关键媒介.

研究的目的:

设计和合成新型 thiazoleamide 衍生物作为强效和选择性的 CYP1B1 抑制剂.
评估这些化合物在克服帕克利塔塞尔耐药性的有效性及其安全性.

主要方法:

基于结构的药物设计和合成 thiazoleamide 衍生物.
酶动力学研究,基于细胞的测定 (复敏化,迁移,入侵),体外代谢,药物动力学研究和分子动力学模拟.

主要成果:

化合物B20通过竞争性机制证明了对CYP1B1的强大和选择性抑制.
B20重新敏感化了抗帕克利塔塞尔的细胞,抑制了A549/T细胞的迁移和入侵,并显示出有利的瘤/正常细胞选择性.
在大鼠中,B20在体外表现出极好的代谢稳定性和有利的药理动力学特性. 分子动力学证实了对CYP1B1.1.的稳定结合.

结论:

B20是通过向抑制CYP1B1克服帕克利塔塞尔耐药性的有希望的候选药物.
该化合物的选择性,有效性和有利的药理动力学特征支持其进一步用于癌症治疗的开发.

更多相关视频

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...